Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZGet Free Report) in a research note issued on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Up 1.7 %

ENZ opened at $0.53 on Wednesday. The firm’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.95. Enzo Biochem has a fifty-two week low of $0.41 and a fifty-two week high of $1.40.

Enzo Biochem (NYSE:ENZGet Free Report) last issued its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Institutional Investors Weigh In On Enzo Biochem

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in Enzo Biochem in the 4th quarter valued at $35,000. BBR Partners LLC acquired a new position in Enzo Biochem during the third quarter worth $112,000. Lepercq De Neuflize Asset Management LLC bought a new position in shares of Enzo Biochem during the fourth quarter valued at $88,000. Wittenberg Investment Management Inc. boosted its stake in shares of Enzo Biochem by 60.1% in the 4th quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 70,400 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares in the last quarter. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Company Profile

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Further Reading

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.